A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

876

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Intismeran
BIOLOGICAL: Pembrolizumab coformulated with berahyaluronidase alfa
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]